

Peter Croucher

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5794712/peter-croucher-publications-by-citations.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

185
papers

10,126
citations

57
h-index

95
g-index

199
ext. papers

11,595
ext. citations

7
avg, IF

5.96
L-index

| # | Paper | IF | Citations |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 185 | Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. <i>British Journal of Haematology</i> , 1997 , 98, 665-72 | 4.5 | 358 |
| 184 | Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. <i>Blood</i> , 2001 , 98, 3534-40 | 2.2 | 324 |
| 183 | Bone metastasis: the importance of the neighbourhood. <i>Nature Reviews Cancer</i> , 2016 , 16, 373-86 | 31.3 | 275 |
| 182 | An atlas of genetic influences on osteoporosis in humans and mice. <i>Nature Genetics</i> , 2019 , 51, 258-266 | 36.3 | 270 |
| 181 | The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. <i>British Journal of Cancer</i> , 2001 , 84, 1126-34 | 8.7 | 262 |
| 180 | Identification of 153 new loci associated with heel bone mineral density and functional involvement of GPC6 in osteoporosis. <i>Nature Genetics</i> , 2017 , 49, 1468-1475 | 36.3 | 235 |
| 179 | Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. <i>Nature Communications</i> , 2015 , 6, 8983 | 17.4 | 232 |
| 178 | Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. <i>Journal of Bone and Mineral Research</i> , 2003 , 18, 482-92 | 6.3 | 212 |
| 177 | Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 425-36 | 6.3 | 208 |
| 176 | Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2006 , 135, 688-92 | 4.5 | 197 |
| 175 | The pharmacology of bisphosphonates and new insights into their mechanisms of action. <i>Journal of Bone and Mineral Research</i> , 1999 , 14 Suppl 2, 53-65 | 6.3 | 188 |
| 174 | Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. <i>Cancer Research</i> , 2002 , 62, 1619-23 | 10.1 | 182 |
| 173 | Bisphosphonates: pharmacology, mechanisms of action and clinical uses. <i>Osteoporosis International</i> , 1999 , 9 Suppl 2, S66-80 | 5.3 | 179 |
| 172 | The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. <i>Cancer Research</i> , 1998 , 58, 5294-7 | 10.1 | 172 |
| 171 | The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. <i>Annals of Oncology</i> , 2009 , 20, 1303-17 | 10.3 | 171 |
| 170 | The Fas/Fas ligand system inhibits differentiation of murine osteoblasts but has a limited role in osteoblast and osteoclast apoptosis. <i>Journal of Immunology</i> , 2007 , 178, 3379-89 | 5.3 | 171 |
| 169 | Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. <i>Cancer Research</i> , 2003 , 63, 912-6 | 10.1 | 158 |

| | | | |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----|
| 168 | Effect of diet-induced weight loss on total body bone mass. <i>Clinical Science</i> , 1992 , 82, 429-32 | 6.5 | 141 |
| 167 | Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. <i>International Journal of Cancer</i> , 2006 , 119, 1728-31 | 7.5 | 139 |
| 166 | Tracking gene expression during zebrafish osteoblast differentiation. <i>Developmental Dynamics</i> , 2009 , 238, 459-66 | 2.9 | 132 |
| 165 | Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. <i>Cancer Research</i> , 2003 , 63, 287-9 | 10.1 | 127 |
| 164 | Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. <i>Clinical Cancer Research</i> , 2014 , 20, 2922-32 | 12.9 | 126 |
| 163 | Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. <i>Immunity</i> , 2003 , 19, 849-61 | 32.3 | 124 |
| 162 | Myeloma bone disease and proteasome inhibition therapies. <i>Blood</i> , 2007 , 110, 1098-104 | 2.2 | 120 |
| 161 | Life-Course Genome-wide Association Study Meta-analysis of Total Body BMD and Assessment of Age-Specific Effects. <i>American Journal of Human Genetics</i> , 2018 , 102, 88-102 | 11 | 119 |
| 160 | Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. <i>Blood</i> , 2017 , 129, 3452-3464 | 2.2 | 117 |
| 159 | Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 2633-46 | 6.3 | 117 |
| 158 | Structural mechanisms of trabecular bone loss in man. <i>Bone and Mineral</i> , 1989 , 6, 339-50 | | 114 |
| 157 | The dormant cancer cell life cycle. <i>Nature Reviews Cancer</i> , 2020 , 20, 398-411 | 31.3 | 107 |
| 156 | Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 7604-9 | 11.5 | 106 |
| 155 | The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. <i>Leukemia</i> , 2008 , 22, 2247-56 | 10.7 | 106 |
| 154 | Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer. <i>Cancer Discovery</i> , 2015 , 5, 35-42 | 24.4 | 104 |
| 153 | Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?. <i>Breast Cancer Research and Treatment</i> , 2005 , 92, 207-15 | 4.4 | 103 |
| 152 | Metastasis and bone loss: advancing treatment and prevention. <i>Cancer Treatment Reviews</i> , 2010 , 36, 615-20 | 14.4 | 100 |
| 151 | Multiple myeloma biology: lessons from the 5TMM models. <i>Immunological Reviews</i> , 2003 , 194, 196-206 | 11.3 | 98 |

| | | | |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----|
| 150 | Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies. <i>Biochemical and Biophysical Research Communications</i> , 1997 , 235, 437-42 | 3.4 | 97 |
| 149 | Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. <i>Clinical and Experimental Metastasis</i> , 2006 , 23, 291-300 | 4.7 | 92 |
| 148 | Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. <i>Journal of Biological Chemistry</i> , 2007 , 282, 31601-9 | 5.4 | 88 |
| 147 | Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 2688-96 | 6.3 | 87 |
| 146 | The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis. <i>Journal of Cellular Physiology</i> , 2018 , 233, 1156-1167 | 7 | 85 |
| 145 | The effects of gonadotrophin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis. <i>Bone</i> , 1995 , 16, 261-7 | 4.7 | 82 |
| 144 | Assessment of cancellous bone structure: comparison of strut analysis, trabecular bone pattern factor, and marrow space star volume. <i>Journal of Bone and Mineral Research</i> , 1996 , 11, 955-61 | 6.3 | 77 |
| 143 | MDC-9 (ADAM-9/Meltrin gamma) functions as an adhesion molecule by binding the alpha(v)beta(5) integrin. <i>Biochemical and Biophysical Research Communications</i> , 2001 , 280, 574-80 | 3.4 | 77 |
| 142 | Bone metastases. <i>Nature Reviews Disease Primers</i> , 2020 , 6, 83 | 51.1 | 77 |
| 141 | Human myeloma cells shed the interleukin-6 receptor: inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor. <i>British Journal of Haematology</i> , 1998 , 101, 694-702 | 4.5 | 76 |
| 140 | Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma. <i>British Journal of Haematology</i> , 1999 , 104, 350-7 | 4.5 | 75 |
| 139 | An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. <i>Cancer Research</i> , 2007 , 67, 202-8 | 10.1 | 73 |
| 138 | Histomorphometric assessment of trabecular bone remodelling in osteoporosis. <i>Bone and Mineral</i> , 1991 , 14, 91-102 | | 70 |
| 137 | Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. <i>Endocrine-Related Cancer</i> , 2014 , 21, 769-81 | 5.7 | 67 |
| 136 | Reduced bone formation in patients with osteoporosis associated with inflammatory bowel disease. <i>Osteoporosis International</i> , 1993 , 3, 236-41 | 5.3 | 67 |
| 135 | A RhoA-FRET Biosensor Mouse for Intravital Imaging in Normal Tissue Homeostasis and Disease Contexts. <i>Cell Reports</i> , 2017 , 21, 274-288 | 10.6 | 65 |
| 134 | Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. <i>American Journal of Pathology</i> , 2008 , 172, 256-64 | 5.8 | 65 |
| 133 | Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. <i>Cancer Research</i> , 2009 , 69, 5307-11 | 10.1 | 64 |

| | | | |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----|
| 132 | Rapid-throughput skeletal phenotyping of 100 knockout mice identifies 9 new genes that determine bone strength. <i>PLoS Genetics</i> , 2012 , 8, e1002858 | 6 | 62 |
| 131 | Single Cell RNA Sequencing of Rare Immune Cell Populations. <i>Frontiers in Immunology</i> , 2018 , 9, 1553 | 8.4 | 61 |
| 130 | Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts. <i>British Journal of Haematology</i> , 2000 , 108, 383-90 | 4.5 | 59 |
| 129 | Bone disease in multiple myeloma. <i>British Journal of Haematology</i> , 1998 , 103, 902-10 | 4.5 | 57 |
| 128 | A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. <i>Blood</i> , 2019 , 134, 30-43 | 2.2 | 54 |
| 127 | A computerised technique for the quantitative assessment of resorption cavities in trabecular bone. <i>Bone</i> , 1990 , 11, 241-5 | 4.7 | 54 |
| 126 | Significant deterioration in nanomechanical quality occurs through incomplete extrafibrillar mineralization in rachitic bone: evidence from in-situ synchrotron X-ray scattering and backscattered electron imaging. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 876-90 | 6.3 | 53 |
| 125 | Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. <i>International Journal of Cancer</i> , 2007 , 121, 1857-61 | 7.5 | 53 |
| 124 | Elevated serum intact parathyroid hormone levels in elderly patients with hip fracture. <i>Clinical Endocrinology</i> , 1989 , 31, 667-72 | 3.4 | 53 |
| 123 | Memory B cells are reactivated in subcapsular proliferative foci of lymph nodes. <i>Nature Communications</i> , 2018 , 9, 3372 | 17.4 | 50 |
| 122 | Glycogen synthase kinase-3 β inhibition promotes in vivo amplification of endogenous mesenchymal progenitors with osteogenic and adipogenic potential and their differentiation to the osteogenic lineage. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 811-21 | 6.3 | 50 |
| 121 | Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. <i>Prostate</i> , 2004 , 59, 304-10 | 4.2 | 50 |
| 120 | Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. <i>Cell</i> , 2021 , 184, 1330-1347 | 36.2 | 49 |
| 119 | Bisphosphonates in preclinical bone oncology. <i>Bone</i> , 2011 , 49, 66-70 | 4.7 | 46 |
| 118 | The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models. <i>Leukemia</i> , 2009 , 23, 1894-903 | 10.7 | 45 |
| 117 | OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. <i>International Journal of Cancer</i> , 2015 , 137, 968-77 | 7.5 | 44 |
| 116 | Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo. <i>Acta Pharmacologica Sinica</i> , 2013 , 34, 699-709 | 8 | 44 |
| 115 | Tumor-host cell interactions in the bone disease of myeloma. <i>Bone</i> , 2011 , 48, 121-8 | 4.7 | 44 |

| | | | |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----|
| 114 | Mitotic quiescence, but not unique "stemness," marks the phenotype of bone metastasis-initiating cells in prostate cancer. <i>FASEB Journal</i> , 2015 , 29, 3141-50 | 0.9 | 43 |
| 113 | A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer. <i>Leukemia</i> , 2007 , 21, 2181-91 | 10.7 | 43 |
| 112 | Age-related changes in resorption cavity characteristics in human trabecular bone. <i>Osteoporosis International</i> , 1991 , 1, 257-61 | 5.3 | 43 |
| 111 | Alterations in the self-renewal and differentiation ability of bone marrow mesenchymal stem cells in a mouse model of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2010 , 12, R149 | 5.7 | 42 |
| 110 | Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance. <i>British Journal of Haematology</i> , 1998 , 101, 287-95 | 4.5 | 42 |
| 109 | Thyroid hormone receptor β mutation causes a severe and thyroxine-resistant skeletal dysplasia in female mice. <i>Endocrinology</i> , 2014 , 155, 3699-712 | 4.8 | 41 |
| 108 | Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma. <i>Cancer Research</i> , 2007 , 67, 4572-7 | 10.1 | 40 |
| 107 | Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model. <i>American Journal of Pathology</i> , 2004 , 165, 869-78 | 5.8 | 40 |
| 106 | Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway. <i>Leukemia</i> , 2012 , 26, 2546-9 | 10.7 | 39 |
| 105 | Bone turnover in non-steroid treated rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 1994 , 53, 163-6 | 2.4 | 39 |
| 104 | A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 12207-12 | 11.5 | 38 |
| 103 | The frequency of osteolytic bone metastasis is determined by conditions of the soil, not the number of seeds; evidence from in vivo models of breast and prostate cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 124 | 12.8 | 36 |
| 102 | Expression of members of a novel membrane linked metalloproteinase family (ADAM) in human articular chondrocytes. <i>Biochemical and Biophysical Research Communications</i> , 1997 , 230, 335-9 | 3.4 | 36 |
| 101 | Regulation of neural crest cell fate by the retinoic acid and Pparg signalling pathways. <i>Development (Cambridge)</i> , 2010 , 137, 389-94 | 6.6 | 34 |
| 100 | Thyrostimulin Regulates Osteoblastic Bone Formation During Early Skeletal Development. <i>Endocrinology</i> , 2015 , 156, 3098-113 | 4.8 | 33 |
| 99 | HIF-2 β Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1. <i>Cancer Research</i> , 2017 , 77, 5452-5463 | 10.1 | 33 |
| 98 | Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. <i>Cancer</i> , 2003 , 97, 818-24 | 6.4 | 32 |
| 97 | The relationship between resorption depth and mean interstitial bone thickness: age-related changes in man. <i>Calcified Tissue International</i> , 1989 , 45, 15-9 | 3.9 | 32 |

| | | | |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----|
| 96 | The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma. <i>British Journal of Haematology</i> , 2000 , 111, 283-6 | 4.5 | 31 |
| 95 | Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo. <i>Neoplasia</i> , 2019 , 21, 777-787 | 6.4 | 30 |
| 94 | Next generation mapping reveals novel large genomic rearrangements in prostate cancer. <i>Oncotarget</i> , 2017 , 8, 23588-23602 | 3.3 | 30 |
| 93 | In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+) 5T multiple myeloma cells. <i>Experimental Hematology</i> , 2001 , 29, 77-84 | 3.1 | 29 |
| 92 | Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. <i>EMBO Reports</i> , 2020 , 21, e50162 | 6.5 | 28 |
| 91 | Geranylgeranyl transferase type II inhibition prevents myeloma bone disease. <i>Biochemical and Biophysical Research Communications</i> , 2008 , 377, 453-457 | 3.4 | 28 |
| 90 | A mouse model for spondyloepiphyseal dysplasia congenita with secondary osteoarthritis due to a Col2a1 mutation. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 413-28 | 6.3 | 27 |
| 89 | ADAM-9 (MDC-9/meltrin-gamma), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the alpha(v)beta5 integrin. <i>Blood</i> , 2006 , 107, 3271-8 | 2.2 | 26 |
| 88 | Myeloma cells (5TMM) and their interactions with the marrow microenvironment. <i>Blood Cells, Molecules, and Diseases</i> , 2004 , 33, 111-9 | 2.1 | 26 |
| 87 | Evidence of a role for a non-matrix-type metalloproteinase activity in the shedding of syndecan-1 from human myeloma cells. <i>British Journal of Haematology</i> , 2001 , 114, 414-21 | 4.5 | 26 |
| 86 | Effects of hormone replacement therapy on cancellous bone microstructure in postmenopausal women. <i>Bone</i> , 1996 , 19, 69-72 | 4.7 | 26 |
| 85 | Genome-wide association study of extreme high bone mass: Contribution of common genetic variation to extreme BMD phenotypes and potential novel BMD-associated genes. <i>Bone</i> , 2018 , 114, 62-71 | 4.7 | 25 |
| 84 | Fas receptor is required for estrogen deficiency-induced bone loss in mice. <i>Laboratory Investigation</i> , 2010 , 90, 402-13 | 5.9 | 25 |
| 83 | Quantitative analysis of trabecular bone structure. <i>Bone</i> , 1993 , 14, 187-92 | 4.7 | 24 |
| 82 | Rapid phenotyping of knockout mice to identify genetic determinants of bone strength. <i>Journal of Endocrinology</i> , 2016 , 231, R31-46 | 4.7 | 24 |
| 81 | An N-ethyl-N-nitrosourea induced corticotropin-releasing hormone promoter mutation provides a mouse model for endogenous glucocorticoid excess. <i>Endocrinology</i> , 2014 , 155, 908-22 | 4.8 | 23 |
| 80 | Structural mechanisms of trabecular bone loss in primary osteoporosis: specific disease mechanism or early ageing?. <i>Bone and Mineral</i> , 1994 , 25, 111-21 | | 23 |
| 79 | Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma. <i>PLoS ONE</i> , 2012 , 7, e41127 | 3.7 | 23 |

| | | | |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----|
| 78 | Evidence of a role for RANKL in the development of myeloma bone disease. <i>Current Opinion in Pharmacology</i> , 2004 , 4, 340-6 | 5.1 | 21 |
| 77 | The 5T2MM murine model of multiple myeloma: maintenance and analysis. <i>Methods in Molecular Medicine</i> , 2005 , 113, 191-205 | | 21 |
| 76 | Anti-tumour activity of bisphosphonates in human myeloma cells. <i>Leukemia and Lymphoma</i> , 1998 , 32, 129-38 | 1.9 | 21 |
| 75 | Low prevalence of osteomalacia in elderly patients with hip fracture. <i>Age and Ageing</i> , 1991 , 20, 132-4 | 3 | 21 |
| 74 | Mice lacking the calcineurin inhibitor Rcan2 have an isolated defect of osteoblast function. <i>Endocrinology</i> , 2012 , 153, 3537-48 | 4.8 | 20 |
| 73 | Bone morphogenetic proteins and receptors are over-expressed in bone-marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes. <i>Leukemia Research</i> , 2010 , 34, 742-51 ^{2.7} | 2.7 | 20 |
| 72 | The Forkhead Transcription Factor FOXP2 Is Required for Regulation of p21WAF1/CIP1 in 143B Osteosarcoma Cell Growth Arrest. <i>PLoS ONE</i> , 2015 , 10, e0128513 | 3.7 | 19 |
| 71 | Signaling between tumor cells and the host bone marrow microenvironment. <i>Calcified Tissue International</i> , 2014 , 94, 125-39 | 3.9 | 19 |
| 70 | Bisphosphonates--mechanisms of action in multiple myeloma. <i>Acta Oncologica</i> , 2000 , 39, 829-35 | 3.2 | 19 |
| 69 | Cloning of a novel membrane-linked metalloproteinase from human myeloma cells. <i>Biochemical Journal</i> , 1996 , 318 (Pt 2), 459-62 | 3.8 | 19 |
| 68 | Reduced bone formation in non-steroid treated patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 1989 , 48, 483-7 | 2.4 | 19 |
| 67 | A Rare Mutation in SMAD9 Associated With High Bone Mass Identifies the SMAD-Dependent BMP Signaling Pathway as a Potential Anabolic Target for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 92-105 | 6.3 | 19 |
| 66 | Slc20a2, Encoding the Phosphate Transporter PIT2, Is an Important Genetic Determinant of Bone Quality and Strength. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 1101-1114 | 6.3 | 18 |
| 65 | Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790. <i>International Journal of Cancer</i> , 2009 , 125, 1177-85 | 7.5 | 18 |
| 64 | Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo. <i>International Journal of Cancer</i> , 2007 , 120, 1657-63 | 7.5 | 18 |
| 63 | Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment. <i>Leukemia</i> , 2007 , 21, 805-12 | 10.7 | 18 |
| 62 | Human myeloma cells promote the recruitment of osteoblast precursors: mediation by interleukin-6 and soluble interleukin-6 receptor. <i>Journal of Bone and Mineral Research</i> , 2000 , 15, 1935-43 ^{6.3} | 6.3 | 17 |
| 61 | Comparison between the lengths of individual osteoid seams and resorption cavities in human iliac crest cancellous bone. <i>Bone and Mineral</i> , 1993 , 23, 27-33 | | 16 |

| | | | |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----|
| 60 | Prader-Willi Critical Region, a Non-Translated, Imprinted Central Regulator of Bone Mass: Possible Role in Skeletal Abnormalities in Prader-Willi Syndrome. <i>PLoS ONE</i> , 2016 , 11, e0148155 | 3.7 | 16 |
| 59 | The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation in vitro: defining the stromal defect in myeloma. <i>British Journal of Haematology</i> , 2014 , 167, 194-206 | 4.5 | 15 |
| 58 | A mouse with an N-Ethyl-N-nitrosourea (ENU) Induced Trp589Arg Galnt3 mutation represents a model for hyperphosphataemic familial tumoural calcinosis. <i>PLoS ONE</i> , 2012 , 7, e43205 | 3.7 | 15 |
| 57 | Targeting RANK/RANKL in the treatment of solid tumours and myeloma. <i>Current Pharmaceutical Design</i> , 2010 , 16, 1272-83 | 3.3 | 15 |
| 56 | Clinical disorders of bone resorption. <i>Novartis Foundation Symposium</i> , 2001 , 232, 251-67; discussion 267-71 | | 15 |
| 55 | N-ethyl-N-Nitrosourea (ENU) induced mutations within the klotho gene lead to ectopic calcification and reduced lifespan in mouse models. <i>PLoS ONE</i> , 2015 , 10, e0122650 | 3.7 | 15 |
| 54 | Cancer Cell Dormancy in Metastasis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020 , 10, | 5.4 | 14 |
| 53 | Loss of the Vitamin D Receptor in Human Breast Cancer Cells Promotes Epithelial to Mesenchymal Cell Transition and Skeletal Colonization. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 1721-1732 | 6.3 | 13 |
| 52 | Hedgehog signalling is required for perichondral osteoblast differentiation in zebrafish. <i>Mechanisms of Development</i> , 2011 , 128, 141-52 | 1.7 | 13 |
| 51 | Anti-Sclerostin Treatment Prevents Multiple Myeloma Induced Bone Loss and Reduces Tumor Burden. <i>Blood</i> , 2015 , 126, 119-119 | 2.2 | 13 |
| 50 | Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model. <i>British Journal of Haematology</i> , 2016 , 172, 64-79 | 4.5 | 13 |
| 49 | DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment. <i>Neoplasia</i> , 2017 , 19, 972-981 | 6.4 | 12 |
| 48 | Evidence for interrupted bone resorption in human iliac cancellous bone. <i>Journal of Bone and Mineral Research</i> , 1995 , 10, 1537-43 | 6.3 | 12 |
| 47 | The relationship between spinal trabecular bone mineral content and iliac crest trabecular bone volume. <i>Calcified Tissue International</i> , 1990 , 46, 162-5 | 3.9 | 12 |
| 46 | Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo. <i>PLoS ONE</i> , 2012 , 7, e35830 | 3.7 | 12 |
| 45 | Osteocyte transcriptome mapping identifies a molecular landscape controlling skeletal homeostasis and susceptibility to skeletal disease. <i>Nature Communications</i> , 2021 , 12, 2444 | 17.4 | 12 |
| 44 | Accelerating functional gene discovery in osteoarthritis. <i>Nature Communications</i> , 2021 , 12, 467 | 17.4 | 12 |
| 43 | An Essential Physiological Role for MCT8 in Bone in Male Mice. <i>Endocrinology</i> , 2017 , 158, 3055-3066 | 4.8 | 11 |

| | | | |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----|
| 42 | A trans-eQTL network regulates osteoclast multinucleation and bone mass. <i>ELife</i> , 2020 , 9, | 8.9 | 10 |
| 41 | Homozygous Dkk1 Knockout Mice Exhibit High Bone Mass Phenotype Due to Increased Bone Formation. <i>Calcified Tissue International</i> , 2018 , 102, 105-116 | 3.9 | 10 |
| 40 | Mice with an N-Ethyl-N-Nitrosourea (ENU) Induced Tyr209Asn Mutation in Natriuretic Peptide Receptor 3 (NPR3) Provide a Model for Kyphosis Associated with Activation of the MAPK Signaling Pathway. <i>PLoS ONE</i> , 2016 , 11, e0167916 | 3.7 | 9 |
| 39 | Melphalan modifies the bone microenvironment by enhancing osteoclast formation. <i>Oncotarget</i> , 2017 , 8, 68047-68058 | 3.3 | 8 |
| 38 | Interleukin-6 receptor shedding: a possible role for members of the ADAM family. <i>Biochemical Society Transactions</i> , 1999 , 27, 224-8 | 5.1 | 8 |
| 37 | Mouse mutant phenotyping at scale reveals novel genes controlling bone mineral density. <i>PLoS Genetics</i> , 2020 , 16, e1009190 | 6 | 8 |
| 36 | Sostdc1: A soluble BMP and Wnt antagonist that is induced by the interaction between myeloma cells and osteoblast lineage cells. <i>Bone</i> , 2019 , 122, 82-92 | 4.7 | 8 |
| 35 | Assessment of resorption cavity characteristics in trabecular bone: changes in primary and secondary osteoporosis. <i>Bone</i> , 1993 , 14, 449-54 | 4.7 | 7 |
| 34 | Inhibition of p38MAPK Reduces Tumor Burden, Prevents the Development of Myeloma Bone Disease, and Increases Survival in the 5T2 and 5T33 Murine Models of Myeloma.. <i>Blood</i> , 2006 , 108, 3436-3436 | 3.2 | 7 |
| 33 | The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of Dickkopf-1, RANKL, MIP-1 and Angiogenic Cytokines.. <i>Blood</i> , 2006 , 108, 3541-3541 | 2.2 | 7 |
| 32 | Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study. <i>Blood Advances</i> , 2021 , 5, 725-736 | 7.8 | 7 |
| 31 | PYY is a negative regulator of bone mass and strength. <i>Bone</i> , 2019 , 127, 427-435 | 4.7 | 6 |
| 30 | A mouse model of early-onset renal failure due to a xanthine dehydrogenase nonsense mutation. <i>PLoS ONE</i> , 2012 , 7, e45217 | 3.7 | 6 |
| 29 | Parathyroid Hormone (PTH) Increases Skeletal Tumour Growth and Alters Tumour Distribution in an In Vivo Model of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2018 , 19, | 6.3 | 6 |
| 28 | Bisphosphonate therapy in the treatment of multiple myeloma. <i>Current Pharmaceutical Design</i> , 2010 , 16, 3028-36 | 3.3 | 5 |
| 27 | Characteristics of trabecular bone resorption cavities in patients with chronic renal failure. <i>Bone and Mineral</i> , 1992 , 16, 139-7 | | 5 |
| 26 | The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis. <i>Cancers</i> , 2020 , 12, | 6.6 | 5 |
| 25 | Bone Mineral Content and Density. <i>Current Protocols in Mouse Biology</i> , 2012 , 2, 365-400 | 1.1 | 5 |

| | | | |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|---|
| 24 | Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations. <i>Journal of Bone Oncology</i> , 2021 , 29, 1003-1015 | 4.5 | 4 |
| 23 | Regenerating zebrafish scales express a subset of evolutionary conserved genes involved in human skeletal disease.. <i>BMC Biology</i> , 2022 , 20, 21 | 7.3 | 3 |
| 22 | Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo. <i>Haematologica</i> , 2021 , 106, 3176-3187 | 6.6 | 3 |
| 21 | Osteocyte Transcriptome Mapping Identifies a Molecular Landscape Controlling Skeletal Homeostasis and Susceptibility to Skeletal Disease | | 3 |
| 20 | An Atlas of Human and Murine Genetic Influences on Osteoporosis | | 3 |
| 19 | Growth Factors 2006 , 99-113 | | 2 |
| 18 | Gene expression predicts dormant metastatic breast cancer cell phenotype.. <i>Breast Cancer Research</i> , 2022 , 24, 10 | 8.3 | 2 |
| 17 | Multiple Myeloma Progression: Dependence on Bone Marrow Adipose Tissue. <i>Blood</i> , 2016 , 128, 3262-3262 | | 2 |
| 16 | An -Ethyl--Nitrosourea (ENU) Mutagenized Mouse Model for Autosomal Dominant Nonsyndromic Kyphoscoliosis Due to Vertebral Fusion. <i>JBMR Plus</i> , 2018 , 2, 154-163 | 3.9 | 1 |
| 15 | Tracking gene expression during zebrafish osteoblast differentiation. <i>Developmental Dynamics</i> , 2009 , 238, spcone-spcone | 2.9 | 1 |
| 14 | Reply to salomo and gimsing. <i>British Journal of Haematology</i> , 2001 , 113, 842-842 | 4.5 | 1 |
| 13 | Bortezomib Reduces Serum Dickkopf-1 and RANKL Concentrations and Normalizes Indices of Bone Remodeling in Patients with Relapsed Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 506-506 | 2.2 | 1 |
| 12 | Accelerating functional gene discovery in osteoarthritis | | 1 |
| 11 | Targeting CDK4/CDK6 Impairs Osteoclast Progenitor Pool Expansion and Blocks Osteolytic Lesion Development in Multiple Myeloma.. <i>Blood</i> , 2009 , 114, 298-298 | 2.2 | 0 |
| 10 | Bisphosphonates in multiple myeloma. <i>Pathologie Et Biologie</i> , 1999 , 47, 178-81 | | 0 |
| 9 | Osteoblastic Metastases 2006 , 41-50 | | |
| 8 | The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma. <i>British Journal of Haematology</i> , 2000 , 111, 283-286 | 4.5 | |
| 7 | Multi-Targeting DKK1 and LRP6 Prevents Myeloma-Induced Bone Disease. <i>Blood</i> , 2021 , 138, 1605-1605 | 2.2 | |

6 Inhibiting cytokine-processing enzymes **2000**, 103-122

5 Gene Modified Human Mesenchymal Stem Cells Expressing Osteoprotegerin Inhibit Osteoclast Activation and Increase Trabecular Bone Area in a Xenogeneic Murine Model of Myeloma.. *Blood*, **2006**, 108, 505-505 2.2

4 In Vivo Evaluation of a BAFF Inhibitor AMG 523 Suggests Lack of Efficacy in Multiple Myeloma Tumor Models.. *Blood*, **2007**, 110, 1518-1518 2.2

3 Murine Models of Myeloma Bone Disease: The Importance of Choice **2010**, 151-168

2 The Effect of Myeloma Cells on Bone Homeostasis Is Heterogenous and Correlates with Underlying Genetic Lesions and Bone Disease In Vivo. *Blood*, **2010**, 116, 4052-4052 2.2

1 The RANKL system and the development of tumor-induced bone disease: lessons from pre-clinical models. *Journal of Musculoskeletal Neuronal Interactions*, **2004**, 4, 285-92 1.3